Ayuda
Ir al contenido

Dialnet


Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma

    1. [1] Hospital Regional Universitario de Málaga

      Hospital Regional Universitario de Málaga

      Málaga, España

    2. [2] Hospital Clínico San Carlos de Madrid

      Hospital Clínico San Carlos de Madrid

      Madrid, España

    3. [3] Harvard Medical School

      Harvard Medical School

      City of Boston, Estados Unidos

    4. [4] Hospital Universitario Madrid Norte Sanchinarro, España
    5. [5] Hospital Universitari i Politècnic La Fe, España
  • Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 10 (October 2017), 2017, págs. 1193-1198
  • Idioma: inglés
  • Texto completo no disponible (Saber más ...)
  • Resumen
    • Nowadays and given the improvement in response rate with the new schemes of treatment with chemotherapy, the interest in neoadjuvant treatment for pancreatic ductal adenocarcinoma, allowing the early application of systemic therapies, has also increased. However, treatment selection fundamentally depends on decisions taken by multidisciplinary committees due to the absence of randomized trials on this indication and because the available evidence is based primarily on small studies. The present manuscript tries to establish recommendations based on the available evidence and expert opinion to correctly select the indication, the type of treatment, as well as its duration and how to correctly follow-up patients during treatment with chemotherapy.


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus

Opciones de compartir

Opciones de entorno